News & Events
News & Events
Institut Pasteur Korea and Masan National Tuberculosis Hospital signed MOU for a joint research on a first-in-class tuberculosis drug development
2018-01-09
Pangyo, Gyeonggi, 9 January, 2018 | On 5 January, 2018, Institut Pasteur Korea (IPK, CEO: Dr. Wang-Shick Ryu) and the Masan National Tuberculosis Hospital (MNTH, President: Dr. Dae Yeon Kim) signed a MOU for collaborative research on the discovery of new preclinical candidates against tuberculosis (TB).
More than 9 million new cases of TB are reported worldwide every year and about 30,000 new cases are reported each year in Korea. In addition, approximately 4.1% of patients (about 1,600 people) among the 39,000 TB patients are reported as multidrug-resistant (MDR) and rifampin-resistant TB with resistance to currently available therapies and drugs. Therefore, it is urgent to develop new TB drugs.
The IPK has a track record of successfully developing an innovative anti-TB drug, named Q203, and been utilizing state-of-the-art bio imaging technology and drug optimization know-how in TB research. The MNTH is the premier organization for treatment of MDR TB in Korea and has various clinical experiences. Therefore, collaboration between IPK and MNTH is expected to accelerate the development of innovative TB drugs.
Dr. Wang-Shick Ryu, the CEO of IPK, said ”By applying the bio imaging technology to the collaboration, we will be able to accelerate the discovery of new multidrug-resistant tuberculosis drug.”
Dr. Dae Yeon Kim, the president of MNTH, said, "We will maximize the research capacity of the national hospital to develop innovative and safe pre-clinical drug candidates for tuberculosis so as to contribute to the advancement of drug discovery research and related industries in Korea.
# # # # # #
About Institut Pasteur Korea
Institut Pasteur Korea (IPK) is an international research institute focused on addressing global health issues with a combination of cutting edge approaches in order to understand disease mechanisms and develop new treatments. By promoting multi-disciplinary projects, IPK is at the forefront of drug discovery and an economic growth engine that contributes to Korea's scientific intellectual and technical resources. IPK has four core missions of public interest; 1) Research, combining front line biology, IT, and chemistry, with innovative cell-based drug discovery platforms that identify novel molecular targets for potential new therapies to treat diseases, 2) Education, offering a wide range of programming to nurture the development of the next generation of scientists and health professionals, 3) Public Health, working in collaboration with national and international health authorities, and 4) Translation of biomedical discoveries to improve health via technology transfer and industrial partnerships.
IPK is a member of the Institut Pasteur International Network (Network). As a hub institution, IPK plays a key role in the Network, serving as a bridge between Korea and global bio-pharma science, expanding Korea's R&D base collaborative research projects with global alliances.
The institute was established in April 2004 in collaboration with Institut Pasteur Paris and the Korea Institute of Science and Technology (KIST), with support from the Ministry of Science and ICT (MSIT). IPK also has a great supporter in the Gyeonggi Provincial government (2005 – 2015 : Block funding | 2016 – Present : drug discovery co-resarch fund for pharm industries).
More than 9 million new cases of TB are reported worldwide every year and about 30,000 new cases are reported each year in Korea. In addition, approximately 4.1% of patients (about 1,600 people) among the 39,000 TB patients are reported as multidrug-resistant (MDR) and rifampin-resistant TB with resistance to currently available therapies and drugs. Therefore, it is urgent to develop new TB drugs.
The IPK has a track record of successfully developing an innovative anti-TB drug, named Q203, and been utilizing state-of-the-art bio imaging technology and drug optimization know-how in TB research. The MNTH is the premier organization for treatment of MDR TB in Korea and has various clinical experiences. Therefore, collaboration between IPK and MNTH is expected to accelerate the development of innovative TB drugs.
Dr. Wang-Shick Ryu, the CEO of IPK, said ”By applying the bio imaging technology to the collaboration, we will be able to accelerate the discovery of new multidrug-resistant tuberculosis drug.”
Dr. Dae Yeon Kim, the president of MNTH, said, "We will maximize the research capacity of the national hospital to develop innovative and safe pre-clinical drug candidates for tuberculosis so as to contribute to the advancement of drug discovery research and related industries in Korea.
# # # # # #
About Institut Pasteur Korea
Institut Pasteur Korea (IPK) is an international research institute focused on addressing global health issues with a combination of cutting edge approaches in order to understand disease mechanisms and develop new treatments. By promoting multi-disciplinary projects, IPK is at the forefront of drug discovery and an economic growth engine that contributes to Korea's scientific intellectual and technical resources. IPK has four core missions of public interest; 1) Research, combining front line biology, IT, and chemistry, with innovative cell-based drug discovery platforms that identify novel molecular targets for potential new therapies to treat diseases, 2) Education, offering a wide range of programming to nurture the development of the next generation of scientists and health professionals, 3) Public Health, working in collaboration with national and international health authorities, and 4) Translation of biomedical discoveries to improve health via technology transfer and industrial partnerships.
IPK is a member of the Institut Pasteur International Network (Network). As a hub institution, IPK plays a key role in the Network, serving as a bridge between Korea and global bio-pharma science, expanding Korea's R&D base collaborative research projects with global alliances.
The institute was established in April 2004 in collaboration with Institut Pasteur Paris and the Korea Institute of Science and Technology (KIST), with support from the Ministry of Science and ICT (MSIT). IPK also has a great supporter in the Gyeonggi Provincial government (2005 – 2015 : Block funding | 2016 – Present : drug discovery co-resarch fund for pharm industries).